Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SS)
CNY8.60
+0.29 (+3.49%)
CN SHH Healthcare Drug Manufacturers - General
Address
Dongbao New Village 134123
Tonghua, CN
Tonghua, CN
CEO
Chun Sheng Leng
Website
thdb.com
IPO
1994-08-24
ISIN CNE000000H87
Description
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and commercialization of pharmaceutical products. These therapeutics are designed to address diabetes and various cardiovascular conditions within the Chinese market. Its operations are structured across two distinct divisions: pharmaceuticals and building materials. The company's extensive pharmaceutical portfolio features prominent insulin analogues, including insulin glargine, insulin aspart, and insulin lispro. Furthermore, it offers a range of antidiabetic medications, oral hypoglycemic drugs, and medical devices such as Gan Shulin pens and blood glucose meters. Tonghua Dongbao also maintains a strategic partnership with Adocia. Established in 1985, the company is headquartered in Tonghua, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY8.60
+0.29 (+3.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
47M
Beta
0.17
Float Shares
1.13B
Free Float %
57.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.32% | +0.00% | -8.88% | -6.35% | -4.32% | +2.94% | +7.68% | -28.00% | -32.34% | -40.01% | +716.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.60
DCF (Unlevered)
5.72
-33.5%
DCF (Levered)
3.42
-60.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
11.47
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Drug Manufacturers - General: +6.6%+46.7% ★ Q1'26: +14.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+3,200.0% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+43.3% ★ Q1'26: +21.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+50.9% ★ Q1'26: +22.8% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+20.7% ★ Q1'26: +8.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-8.0% ★ Q1'26: +16.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.14× ★ Q1'26: 0.65× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.67B
est: 1.80B (-7.2%)
|
2.04B
est: 1.97B (+3.4%)
|
2.55B
est: 2.51B (+1.4%)
|
2.69B
est: 2.91B (-7.4%)
|
2.78B
est: 2.86B (-3.0%)
|
2.89B
est: 2.96B (-2.2%)
|
3.27B
est: 3.24B (+0.8%)
|
2.78B
est: 2.84B (-2.2%)
|
3.08B
est: 2.45B (+25.6%)
|
2.01B
est: 1.98B (+1.4%)
|
2.95B
est: 2.84B (+3.8%)
|
3.26B
3.23B – 3.28B
+14.8% YoY
|
3.64B
3.48B – 3.73B
+11.5% YoY
|
4.13B
4.12B – 4.14B
+13.6% YoY
|
| EBITDA |
720.06M
est: 672.51M (+7.1%)
|
963.89M
est: 737.34M (+30.7%)
|
1.16B
est: 938.75M (+23.1%)
|
1.16B
est: 1.09B (+7.0%)
|
1.13B
est: 1.07B (+5.2%)
|
1.27B
est: 1.11B (+15.1%)
|
1.68B
est: 1.21B (+38.5%)
|
1.98B
est: 1.06B (+86.6%)
|
1.56B
est: 1.16B (+34.7%)
|
58.09M
est: 936.47M (-93.8%)
|
1.77B
est: 1.34B (+31.9%)
|
1.54B
1.53B – 1.55B
+14.8% YoY
|
1.72B
1.64B – 1.76B
+11.5% YoY
|
1.95B
1.95B – 1.96B
+13.6% YoY
|
| EBIT |
589.21M
est: 562.66M (+4.7%)
|
803.53M
est: 616.90M (+30.3%)
|
988.62M
est: 785.41M (+25.9%)
|
990.55M
est: 909.16M (+9.0%)
|
972.60M
est: 895.18M (+8.6%)
|
1.12B
est: 925.19M (+20.8%)
|
1.53B
est: 1.01B (+51.4%)
|
1.83B
est: 888.08M (+106.1%)
|
1.37B
est: 989.05M (+38.8%)
|
-128.91M
est: 800.21M (-116.1%)
|
1.50B
est: 1.15B (+30.7%)
|
1.32B
1.31B – 1.33B
+14.8% YoY
|
1.47B
1.41B – 1.50B
+11.5% YoY
|
1.67B
1.66B – 1.67B
+13.6% YoY
|
| Net Income |
492.96M
est: 518.45M (-4.9%)
|
640.92M
est: 665.90M (-3.8%)
|
836.55M
est: 857.75M (-2.5%)
|
838.61M
est: 977.81M (-14.2%)
|
811.21M
est: 975.26M (-16.8%)
|
929.92M
est: 962.19M (-3.4%)
|
1.31B
est: 1.36B (-3.6%)
|
1.58B
est: 1.69B (-6.6%)
|
1.17B
est: 452.93M (+157.8%)
|
-42.72M
est: 32.53M (-231.3%)
|
1.22B
est: 1.24B (-1.4%)
|
655.73M
565.05M – 837.84M
-47.0% YoY
|
772.20M
648.58M – 982.67M
+17.8% YoY
|
826.61M
790.87M – 993.65M
+7.0% YoY
|
| SGA |
670.97M
est: 764.97M (-12.3%)
|
720.38M
est: 838.71M (-14.1%)
|
785.92M
est: 1.07B (-26.4%)
|
864.00M
est: 1.24B (-30.1%)
|
1.01B
est: 1.22B (-17.3%)
|
1.09B
est: 1.26B (-13.2%)
|
1.25B
est: 1.38B (-8.9%)
|
1.11B
est: 1.21B (-7.7%)
|
1.05B
est: 987.44M (+6.1%)
|
1.25B
est: 798.90M (+56.7%)
|
787.68M
est: 1.15B (-31.2%)
|
1.32B
1.30B – 1.32B
+14.8% YoY
|
1.47B
1.40B – 1.50B
+11.5% YoY
|
1.67B
1.66B – 1.67B
+13.6% YoY
|
| EPS |
0.25
est: 0.24 (+3.0%)
|
0.32
est: 0.31 (+2.7%)
|
0.41
est: 0.40 (+2.1%)
|
0.41
est: 0.46 (-10.4%)
|
0.40
est: 0.46 (-12.4%)
|
0.46
est: 0.45 (+2.1%)
|
0.64
est: 0.64 (+0.8%)
|
0.79
est: 0.79 (-0.3%)
|
0.59
est: 0.23 (+151.4%)
|
-0.02
est: 0.02 (-220.0%)
|
0.62
est: 0.64 (-3.1%)
|
0.33
0.29 – 0.43
-48.5% YoY
|
0.39
0.33 – 0.50
+19.1% YoY
|
0.44
0.40 – 0.51
+11.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.18B
OE per share TTM
0.60
Owner's Yield
6.63%
Maintenance CapEx ratio
12.11%
Maint CapEx / Avg PPE
88.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 26 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.86% | 608.8K | 0.95% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.1K | 0.15% |
| 3 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 24.3K | 0.40% |
| 4 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 10.7K | 0.58% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 30.7K | 0.46% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.9K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 44.8K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.21M | 0.06% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 114.7K | 0.39% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 119.6K | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
439.6K
Shares Outstanding
1.96B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Sheng Leng | Vice Chairman & GM | — | male |
| Fan Su | Board Secretary | — | female |
| Guodong Zhang | Deputy GM & Director | — | male |
| Junyu Chi | Chief Accountant | — | male |
| Wenhai Zhang | Deputy GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600867.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
